On December 13th, Eli Lilly Pharmaceuticals announced that several of its products (including new indications) will be included in the new version of the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue (2023), including CDK4 in the anti-tumor field; 6 inhibitor selection; Reg; (Abbesili Tablets) HR+, HER2- lymph node positive, high recurrence risk and Ki-67 ≥ 20% early breast cancer adjuvant treatment were included in the medical insurance for the first time, and HR+, HER2- late endocrine sensitivity and late endocrine resistance were successfully renewed; PD-1 inhibitor Dabershu; Reg; New indications for locally advanced or metastatic non-small cell lung cancer with positive EGFR gene mutations that have failed EGFR-TKI treatment have been added to the original medical insurance based on Xindilizumab injection; Immunological IL-17A inhibitor Tuozi& Reg; The indication for plaque psoriasis has been successfully renewed with the addition of indications for ankylosing spondylitis and included in medical insurance; In addition, advanced colorectal cancer drug Aiyoute& Reg; The contract has been successfully renewed for Furoquinib Capsules. The new version of the National Medical Insurance Catalogue will be officially implemented from January 1, 2024.